GMED vs. EW, RMD, IDXX, DXCM, STE, PODD, HOLX, BAX, MASI, and TFX
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), and Teleflex (TFX). These companies are all part of the "health care equipment" industry.
Globus Medical vs.
Edwards Lifesciences (NYSE:EW) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
Edwards Lifesciences has higher revenue and earnings than Globus Medical. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences currently has a consensus target price of $78.48, indicating a potential upside of 13.75%. Globus Medical has a consensus target price of $96.91, indicating a potential upside of 3.92%. Given Edwards Lifesciences' higher probable upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Globus Medical.
Edwards Lifesciences has a net margin of 70.82% compared to Globus Medical's net margin of 3.69%. Edwards Lifesciences' return on equity of 20.76% beat Globus Medical's return on equity.
Edwards Lifesciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 1.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 18.5% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Edwards Lifesciences received 767 more outperform votes than Globus Medical when rated by MarketBeat users. Likewise, 71.00% of users gave Edwards Lifesciences an outperform vote while only 67.74% of users gave Globus Medical an outperform vote.
In the previous week, Edwards Lifesciences had 9 more articles in the media than Globus Medical. MarketBeat recorded 17 mentions for Edwards Lifesciences and 8 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.22 beat Edwards Lifesciences' score of 0.82 indicating that Globus Medical is being referred to more favorably in the news media.
Summary
Edwards Lifesciences beats Globus Medical on 11 of the 18 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
This page (NYSE:GMED) was last updated on 1/23/2025 by MarketBeat.com Staff
Free GMED Stock Alerts